BeyondSpring Inc (BYSI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.72 (+1.72%), Market cap $0.05B, 52-week low–high $1.27 ~ $3.40.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth fac
Financial statements, price targets, institutional (13F) holdings and related news for BeyondSpring Inc are updated in real time on BlackAll Trade.
BeyondSpring Inc trades at $0.72 (+1.72%). Real-time quotes and charts are available on BlackAll Trade.
BeyondSpring Inc has a market cap of about $0.05B.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates thr